journal article·2022-03Open access

Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic

A. Raza, D. Kamato, F.B. Sime, J.A. Roberts, A. Popat, J.R. Falconer, T. Kumeria

Abstract

Advanced materials-based strategies are proving to be promising in solving the major problems of oral drug delivery. Herein, Polyethylene glycol (PEG)-functionalized porous silicon nanoparticles (pSiNPs) containing meropenem (MER) are proposed as a strategy to increase its transport across the intestinal epithelium, while maintaining its antibacterial activity. After surface conjugation of pSiNPs with TPGS (d-α-Tocopherol polyethylene glycol 1000 succinate) and NH2-PEG4-PA (amine PEG4 propionic acid), MER, a last-resort antibacterial drug, was loaded into these NPs with a loading capacity of 27–28.9 wt%. Cellular uptake results in LS174T cells demonstrate efficient cellular uptake of nanoparticles and show their potential to enable transcellular delivery of MER. The bioavailability of MER was significantly improved by all the prepared formulations (i.e., increased absorptive transport and reduced secretory transport). The MER-pSi-TPGS showed the best performance with an efflux ratio (i.e., secretory transport/absorptive transport) of 0.40 which is 5.5 folds less than pure MER (2.62). The in-vitro antibacterial assay showed that these formulations could retain MER's antibacterial activities against Staphylococcus aureus and Pseudomonas aeruginosa. Lastly, results from a modified Caco-2 monolayer model showed that both MER and MER-pSi-TPGS killed the bacteria after permeation, the rate of killing of MER-pSi-TPGS was rapid as compared to MER.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Silicon Nanostructures and Photoluminescence · Carbon and Quantum Dots Applications · Quantum Dots Synthesis And Properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (61)

Show source-provided references
1. Ostroff · 2021 · 2100216
2. Photodynamic therapy for biomodulation and disinfection in implant dentistry: is it feasible and effective?10.1111/php.13434 ↗
3. Codelivery of synovium-derived mesenchymal stem cells and TGF-β by a hybrid scaffold for cartilage regeneration10.1021/acsbiomaterials.8b00483 ↗
4. A. Nara de Souza Rastelli, Antimicrobial photodynamic therapy (aPDT) as a disinfection and biomodulation approach in implant dentistry, Photochem. Photobiol..
5. Nanomaterials for tissue engineering in dentistry10.3390/nano6070134 ↗
6. Tushar Kumeria, Microfluidic assembly of pomegranate-like hierarchical microspheres for efflux regulation in oral drug delivery10.1016/j.actbio.2021.03.042 ↗
7. Coexistence of passive and carrier-mediated processes in drug transport10.1038/nrd3187 ↗
8. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels10.1021/js970372e ↗
9. Raza · 2020
10. Solid nanoparticles for oral antimicrobial drug delivery: a review10.1016/j.drudis.2019.01.004 ↗
11. Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives10.1080/17425247.2017.1317245 ↗
12. Kumeria · 2020
13. Microfluidic nanoassembly of bioengineered chitosan-modified FcRn-targeted porous silicon nanoparticles@ hypromellose acetate succinate for oral delivery of antidiabetic peptides10.1021/acsami.8b20821 ↗
14. Bioinspired zwitterionic polyphosphoester modified porous silicon nanoparticles for efficient oral insulin delivery10.1039/D0BM01772H ↗
15. Engineered multifunctional albumin-decorated porous silicon nanoparticles for FcRn translocation of insulin10.1002/smll.201800462 ↗
16. Porous silicon in drug delivery devices and materials10.1016/j.addr.2008.03.017 ↗
17. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers10.1016/j.ijpharm.2011.02.059 ↗
18. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access10.1021/mp900191s ↗
19. Effects of polyethylene glycols on intestinal efflux pump expression and activity in Caco-2 cells10.1590/S1984-82502015000300026 ↗
20. Recent advances of D-α-tocopherol polyethylene glycol 1000 succinate based stimuli-responsive nanomedicine for cancer treatment10.1007/s11596-020-2185-1 ↗
21. Enhanced intestinal absorption of vancomycin with Labrasol and D-α-tocopheryl PEG 1000 succinate in rats10.1016/S0378-5173(02)00544-6 ↗
22. Ritonavir–PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations10.1002/jps.10566 ↗
23. Size control of porous silicon nanoparticles by electrochemical perforation etching10.1002/ppsc.201300244 ↗
24. TPGS-functionalized polydopamine-modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance10.1002/smll.201700623 ↗
25. Redox-responsive F127-folate/F127-disulfide bond-d-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors10.2147/IJN.S152395 ↗
26. Raza · 2021
27. PLGA encapsulated γ-cyclodextrin-meropenem inclusion complex formulation for oral delivery10.1016/j.ijpharm.2021.120280 ↗
28. Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers10.1186/s40360-017-0129-6 ↗
29. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia10.1016/j.jmii.2019.04.008 ↗
30. A MACEing silicon: towards single-step etching of defined porous nanostructures for biomedicine10.1016/j.pmatsci.2019.100636 ↗
31. Park · 2007 · 66400C
32. Discoidal porous silicon particles: fabrication and biodistribution in breast cancer bearing mice10.1002/adfm.201200869 ↗
33. Formation and Characterization of Mesoporous Silica MCM-48 and Polypyrrole Composite10.1007/s10593-017-2024-x ↗
34. Progress of porous silicon APTES-functionalization by FTIR investigations10.1016/j.apsusc.2015.01.107 ↗
35. Graphene oxide decorated diatom silica particles as new nano-hybrids: towards smart natural drug microcarriers10.1039/c3tb21051k ↗
36. High dispersed phyto-phospholipid complex/TPGS 1000 with mesoporous silica to enhance oral bioavailability of tanshinol10.1016/j.colsurfb.2018.06.013 ↗
37. Highly reactive N, N′-carbonyldiimidazole-tailored bifunctional electrocatalyst for oxygen reduction and oxygen evolution10.1016/j.electacta.2019.03.196 ↗
38. Rheological behavior and film characterization of fumed silica dispersion in carbodiimide based UV-curable coating material10.1007/s13233-013-1012-y ↗
39. Development of Folate-functionalized PEGylated Zein nanoparticles for ligand-directed delivery of paclitaxel10.3390/pharmaceutics11110562 ↗
40. Juère · 2017 · vol. 14 · 4431
41. Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib10.1016/j.biomaterials.2015.02.014 ↗
42. Permeability of rhynchophylline across human intestinal cell in vitro
43. Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder10.1016/j.ejps.2019.02.021 ↗
44. Caco-2 monolayers in experimental and theoretical predictions of drug transport10.1016/S0169-409X(00)00128-9 ↗
45. In vitro and in vivo evaluation of positively charged liposaccharide derivatives as oral absorption enhancers for the delivery of anionic drugs10.1002/jps.21999 ↗
46. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability10.1038/s41551-019-0465-5 ↗
47. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots10.1016/j.biomaterials.2012.01.036 ↗
48. Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability10.3390/pharmaceutics13071103 ↗
49. Effects of polyethylene glycols on intestinal efflux pump expression and activity in Caco-2 cells10.1590/S1984-82502015000300026 ↗
50. Effects of poly (ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers10.1002/jps.10175 ↗
51. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane10.1046/j.1432-1327.2000.01046.x ↗
52. Impact of molecular weight on the mechanism of cellular uptake of polyethylene glycols (PEGs) with particular reference to P-glycoprotein10.1016/j.apsb.2020.02.001 ↗
53. Effect of uremic state in intestine through a co-culture in vitro intestinal epithelial model10.1016/j.ijpharm.2020.119450 ↗
54. Inhibitory effects of commonly used excipients on P-glycoprotein in vitro10.1021/acs.molpharmaceut.8b00482 ↗
55. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles10.1021/nn2033105 ↗
56. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug10.1016/j.jconrel.2008.08.021 ↗
57. Reduced ABCB1 expression and activity in the presence of acrylic copolymers
58. European Committee on AntimicrobialSusceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/QC/v_10.0_EUCAST_QC_tables_routine_and_extended_QC.pdf, (2020).
59. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_QC_Tables_V1.1.pdf, (2010).
60. Commentary: the clinical and laboratory standards Institute (CLSI) subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes10.1128/JCM.01864-19 ↗
61. Polymyxin B induces apoptosis in kidney proximal tubular cells10.1128/AAC.02587-12 ↗